About Cytoki

Cytoki Leadership

Cytoki’s team of experienced executives combine deep expertise in IL-22 biology, lipidation technology and drug development. They are uniquely positioned to leverage the potential of IL-22 as a new treatment paradigm for serious diseases involving epithelial injury.

Our team

Rasmus Jorgensen, PhD


Anne Louise Kjølbye, PhD, MBA

Chief Development Officer

Martijn van de Bunt, MD, DPhil

Vice President of Research

Jens Chr. Norrild, PhD

Vice President of CMC

Karsten Skydsgaard, DVM, E*MBA

Head of Non-Clinical Development

Our board

Christian Elling

Chairperson and Managing Partner, Lundbeckfonden BioCapital

Karen Wagner

Managing Partner, Ysios Capital

Dani Bach

Partner, +ND Capital

Amanda Chaperot

Partner, Seventure Partners

Our investors